Laure Monard

562 total citations
14 papers, 96 citations indexed

About

Laure Monard is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Laure Monard has authored 14 papers receiving a total of 96 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in Laure Monard's work include Sarcoma Diagnosis and Treatment (5 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers). Laure Monard is often cited by papers focused on Sarcoma Diagnosis and Treatment (5 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers). Laure Monard collaborates with scholars based in France, Canada and United States. Laure Monard's co-authors include Sylvie Chabaud, François Bertucci, Vincent Vidal, Valérie Laurence, Elsa Kalbacher, Nicolas Penel, Christine Chevreau, Corinne Delcambre, Nathalie Gaspar and Mathilde Cancel and has published in prestigious journals such as Annals of Surgery, Scientific Reports and British Journal of Cancer.

In The Last Decade

Laure Monard

13 papers receiving 96 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laure Monard France	7	57	54	35	17	17	14	96
Teresa Perra Italy	6	49 0.9×	64 1.2×	77 2.2×	15 0.9×	10 0.6×	12	123
Petra Holečková Czechia	7	63 1.1×	51 0.9×	41 1.2×	62 3.6×	5 0.3×	24	172
Nanjie Xiao China	4	85 1.5×	76 1.4×	43 1.2×	36 2.1×	8 0.5×	11	162
Hatim Karachiwala Canada	6	37 0.6×	58 1.1×	19 0.5×	18 1.1×	21 1.2×	21	147
Stefanie Hecker‐Nolting Germany	7	61 1.1×	21 0.4×	20 0.6×	17 1.0×	10 0.6×	21	88
Mario Domenico Rizzato Italy	8	29 0.5×	48 0.9×	46 1.3×	21 1.2×	31 1.8×	24	120
Fengjiao Zhao China	8	48 0.8×	95 1.8×	35 1.0×	27 1.6×	32 1.9×	15	153
Massimo Oldani Italy	6	93 1.6×	45 0.8×	73 2.1×	33 1.9×	6 0.4×	10	176
Kristen Wong United States	6	23 0.4×	36 0.7×	28 0.8×	26 1.5×	10 0.6×	10	114
Lucia Ilaria Sgaramella Italy	7	41 0.7×	53 1.0×	72 2.1×	14 0.8×	3 0.2×	18	163

Countries citing papers authored by Laure Monard

Since Specialization

Citations

This map shows the geographic impact of Laure Monard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laure Monard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laure Monard more than expected).

Fields of papers citing papers by Laure Monard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laure Monard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laure Monard. The network helps show where Laure Monard may publish in the future.

Co-authorship network of co-authors of Laure Monard

This figure shows the co-authorship network connecting the top 25 collaborators of Laure Monard. A scholar is included among the top collaborators of Laure Monard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laure Monard. Laure Monard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Blanchard, Pierre, Anne Aupérin, David Veyer, et al.. (2025). Intensification or de-escalation? What is the standard treatment for human papillomavirus-related oropharyngeal cancers in 2025?. Cancer/Radiothérapie. 29(5-6). 104674–104674. 1 indexed citations

Bourien, Héloïse, Xavier Adhoute, Boris Campillo‐Gimenez, et al.. (2025). A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data. Digestive and Liver Disease. 57(10). 2011–2015.

Lambert, Aurélien, Julia Salleron, Alexandre Harlé, et al.. (2024). Impact of Positive Resection Margins on Recurrence and Survival After Resection and Adjuvant Chemotherapy in Pancreatic Cancer. Annals of Surgery. 283(4). 651–658. 1 indexed citations

Duffaud, Florence, Jean‐Yves Blay, Axel Le Cesne, et al.. (2023). Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study. British Journal of Cancer. 129(12). 1940–1948. 17 indexed citations

Pastor, Brice, Corinne Prévostel, Evelyne Lopez‐Crapez, et al.. (2023). A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer. Scientific Reports. 13(1). 2739–2739. 6 indexed citations

Salleron, Julia, Thierry Conroy, Frédéric Marchal, et al.. (2022). Preneoplastic Lesions in Surgical Specimens Do Not Worsen the Prognosis of Patients Who Underwent Surgery for Pancreatic Adenocarcinoma: Post-Hoc Analysis of the PRODIGE 24-CCTG PA 6 Trial. Cancers. 14(16). 3945–3945. 3 indexed citations

Edeline, Julien, Satoshi Hirano, Aurélie Bertaut, et al.. (2022). Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. European Journal of Cancer. 164. 80–87. 14 indexed citations

Conroy, Thierry, Pascal Hammel, Anthony Turpin, et al.. (2021). LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC). Annals of Oncology. 32. S1334–S1334. 11 indexed citations

Duffaud, Florence, Sylvie Chabaud, Christine Chevreau, et al.. (2021). LBA58 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer. Annals of Oncology. 32. S1335–S1335. 2 indexed citations

10.

Piperno‐Neumann, Sophie, D. Tran, Hélène Pacquement, et al.. (2021). Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?. Cancers. 13(7). 1683–1683. 10 indexed citations

11.

Duffaud, Florence, Jean‐Yves Blay, Olivier Mir, et al.. (2020). LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER. Annals of Oncology. 31. S1199–S1199. 13 indexed citations

12.

Samalin, Emmanuelle, Anthony Turpin, Faïza Khemissa, et al.. (2019). Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI). Annals of Oncology. 30. iv21–iv21. 2 indexed citations

13.

Duffaud, Florence, Jean‐Yves Blay, Antoîne Italiano, et al.. (2019). Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER. Annals of Oncology. 30. v926–v927. 2 indexed citations

14.

Németh, Antal, René Scheenstra, Ulrich Baumann, et al.. (2016). Oral Tocofersolan Corrects or Prevents Vitamin E Deficiency in Children With Chronic Cholestasis. Journal of Pediatric Gastroenterology and Nutrition. 63(6). 610–615. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact